Scopus: Pharmacokinetics and bioavailability of tolfenamic acid in sheep
dc.contributor.author | Corum O. | |
dc.contributor.author | Corum D.D. | |
dc.contributor.author | Er A. | |
dc.contributor.author | Yildiz R. | |
dc.contributor.author | Uney K. | |
dc.date.accessioned | 2023-04-12T02:08:05Z | |
dc.date.available | 2023-04-12T02:08:05Z | |
dc.date.issued | 2018-12-01 | |
dc.description.abstract | The pharmacokinetics, bioavailability, and tolerability of tolfenamic acid (TA) were determined after treating sheep with TA via different routes and doses. This crossover study was carried out with a washout period of 15 days. In the study, 16 clinically healthy sheep were randomly assigned to two equal groups. In the first group (n = 8), animals received TA by intravenous (IV), intramuscular (IM), subcutaneous (SC), or oral (OR) routes at 2 mg/kg. In the second group (n = 8), TA was administered intravenously to each sheep at 2, 4, 8, and 16 mg/kg. Plasma samples were analyzed with a high-performance liquid chromatography assay. Noncompartmental pharmacokinetic analyses were used to evaluate the data. The area under the concentration–time curves (AUC0−∞), elimination half-life (t1/2ʎz), and the mean residence time (MRT) significantly differed among the administration routes at 2 mg/kg of TA. Following IM, SC, and OR administrations, TA demonstrated different peak concentrations (Cmax) and time to reach Cmax (Tmax), with a bioavailability of 163%, 127%, and 107%, respectively. The dose-normalized AUC0−∞ revealed a significant difference among the dose groups; however, the relationship between dose and AUC0−∞ was linear. Both t1/2ʎz and MRT increased depending on the dose. Although the total clearance (ClT) decreased depending on dose, the volume of distribution at steady-state (Vss) increased. Tolfenamic acid indicated a long half-life and high bioavailability following IM, SC, and OR administrations at 2 mg/kg. TA exhibited linear kinetics and was well tolerated by the animals, except at 16 mg/kg. Thus, TA may be used in different routes and doses (≤8 mg/kg) in sheep; however, further studies are needed to determine the clinical efficacy of TA during the inflammatory and painful conditions and the pharmacokinetics and safety of repeated administration in sheep. | |
dc.identifier.doi | 10.1111/jvp.12702 | |
dc.identifier.issn | 01407783 | |
dc.identifier.pubmed | 30084126 | |
dc.identifier.scopus | 2-s2.0-85052510285 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12597/5219 | |
dc.relation.ispartof | Journal of Veterinary Pharmacology and Therapeutics | |
dc.rights | false | |
dc.subject | bioavailability | pharmacokinetics | sheep | tolerability | tolfenamic acid | |
dc.title | Pharmacokinetics and bioavailability of tolfenamic acid in sheep | |
dc.type | Article | |
dspace.entity.type | Scopus | |
oaire.citation.issue | 6 | |
oaire.citation.volume | 41 | |
person.affiliation.name | Kastamonu University | |
person.affiliation.name | Kastamonu University | |
person.affiliation.name | Selçuk Üniversitesi | |
person.affiliation.name | Mehmet Akif Ersoy Üniversity | |
person.affiliation.name | Selçuk Üniversitesi | |
person.identifier.orcid | 0000-0003-3168-2510 | |
person.identifier.orcid | 0000-0003-1567-991X | |
person.identifier.orcid | 0000-0002-8674-4873 | |
person.identifier.scopus-author-id | 55902904600 | |
person.identifier.scopus-author-id | 57204288970 | |
person.identifier.scopus-author-id | 17434192100 | |
person.identifier.scopus-author-id | 15756686000 | |
person.identifier.scopus-author-id | 8408064700 | |
relation.isPublicationOfScopus | abaf090c-9a42-4d6e-84a1-d5faa25d90d9 | |
relation.isPublicationOfScopus.latestForDiscovery | abaf090c-9a42-4d6e-84a1-d5faa25d90d9 |